Vanadate Impedes Adipogenesis in Mesenchymal Stem Cells Derived from Different Depots within Bone

Area of Science:

• Biomedical Sciences
• Cell Biology
• Orthopedics

Background:

• Glucocorticoid-induced osteoporosis (GIO) increases bone marrow fat, shifting mesenchymal stem cell (MSC) differentiation towards fat (adipogenesis) instead of bone (osteoblastogenesis).
• Vanadate, a protein tyrosine phosphatase inhibitor, previously prevented GIO in rats, but its direct effect on bone-derived MSCs was unknown.

Purpose of the Study:

• To investigate the effect of vanadate on adipogenesis in rat bone marrow MSCs (bmMSCs) and proximal femur MSCs (pfMSCs).
• To characterize differences in adipogenic and osteogenic potential between bmMSCs and pfMSCs.

Main Methods:

• Primary rat bmMSCs and pfMSCs were isolated and characterized for MSC markers (CD90, CD106, CD45, CD26).
• Cells were cultured in osteogenic (OM) or adipogenic (AM) media, with or without vanadate (10 μM) or glucocorticoids (1 μM).
• Lipid accumulation, adipogenic gene expression (PPARγ2, aP2, adipsin), and mineralization were assessed.

Main Results:

• pfMSCs showed faster lipid accumulation (1 week) and slower mineralization (3 weeks) compared to bmMSCs (3 weeks for lipid, 1 week for mineralization).
• Vanadate significantly reduced lipid accumulation and adipogenic gene expression in both cell types when added to AM.
• Glucocorticoids alone did not induce lipid accumulation but caused significant cell death in pfMSCs.

Conclusions:

• The femur contains distinct MSC populations with differing adipogenic and osteogenic potentials, notably pfMSCs exhibiting rapid adipogenesis.
• Vanadate effectively inhibits adipogenesis in bone-derived MSCs, offering a potential therapeutic strategy for GIO.
• Increased bone marrow adiposity in GIO may involve enhanced adipogenesis in MSCs outside the bone marrow niche, not solely direct glucocorticoid effects.